Caladrius Biosciences Inc.

0.5003-0.0287-5.43%Vol 221.48K1Y Perf -66.31%
Jun 24th, 2022 16:00 DELAYED
BID0.4954 ASK0.5376
Open0.5201 Previous Close0.5290
Pre-Market- After-Market0.54
 - -  0.04 7.44%
Target Price
4.50 
Analyst Rating
Moderate Buy 1.67
Potential %
799.46 
Finscreener Ranking
★★★★+ —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★ —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
7.82 
Earnings Rating
Neutral
Market Cap30.28M 
Earnings Date
4th Aug 2022
Alpha-0.03 Standard Deviation0.19
Beta1.10 

Today's Price Range

0.49000.5376

52W Range

0.40191.66

5 Year PE Ratio Range

-1.604.70

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-2.63%
1 Month
6.65%
3 Months
-34.26%
6 Months
-45.02%
1 Year
-66.31%
3 Years
-79.74%
5 Years
-88.88%
10 Years
-98.86%

TickerPriceChg.Chg.%
CLBS0.5003-0.0287-5.43
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.10-0.0730.00
Q04 2021-0.15-0.1126.67
Q03 2021-0.13-0.127.69
Q02 2021-0.15-0.1033.33
Q01 2021-0.09-0.19-111.11
Q04 2020-0.27-0.28-3.70
Q03 2020-0.30-0.293.33
Q02 2020-0.36-0.338.33
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.1078.26Positive
9/2022 QR-0.1079.17Positive
12/2022 FY-0.40--
12/2023 FY-0.36--
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.10
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume221.48K
Shares Outstanding60.52K
Shares Float59.28M
Trades Count299
Dollar Volume114.57K
Avg. Volume190.81K
Avg. Weekly Volume80.04K
Avg. Monthly Volume142.41K
Avg. Quarterly Volume349.98K

Caladrius Biosciences Inc. (NASDAQ: CLBS) stock closed at 0.5003 per share at the end of the most recent trading day (a -5.43% change compared to the prior day closing price) with a volume of 221.48K shares and market capitalization of 30.28M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 27 people. Caladrius Biosciences Inc. CEO is David J. Mazzo.

The one-year performance of Caladrius Biosciences Inc. stock is -66.31%, while year-to-date (YTD) performance is -40.55%. CLBS stock has a five-year performance of -88.88%. Its 52-week range is between 0.4019 and 1.66, which gives CLBS stock a 52-week price range ratio of 7.82%

Caladrius Biosciences Inc. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 0.35, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -23.67%, a ROC of -23.64% and a ROE of -24.53%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Caladrius Biosciences Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.10 for the next earnings report. Caladrius Biosciences Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Caladrius Biosciences Inc. is Moderate Buy (1.67), with a target price of $4.5, which is +799.46% compared to the current price. The earnings rating for Caladrius Biosciences Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Caladrius Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Caladrius Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.44, ATR14 : 0.03, CCI20 : -7.22, Chaikin Money Flow : -0.13, MACD : 0.00, Money Flow Index : 54.78, ROC : -0.89, RSI : 46.31, STOCH (14,3) : 34.61, STOCH RSI : 0.00, UO : 44.80, Williams %R : -65.39), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Caladrius Biosciences Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
2 (66.67 %)
2 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (33.33 %)
1 (33.33 %)
1 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Moderate Buy
1.67
Moderate Buy
1.67

Caladrius Biosciences Inc.

Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company developing cellular therapies designed to reverse, not manage, disease. The company's product candidates include: CLBS119, for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, clinical trial to be initiated in 3Q2020 (USA); CLBS12, recipient of a SAKIGAKE (Japan) and ATMP (Europe) designations, eligible for early conditional approval for the treatment of critical limb ischemia based on an ongoing clinical trial (Japan); CLBS16, subject of the completed proof-of-concept ESCaPE-CMD clinical and planned Phase 2B (U.S.A.); and CLBS14, a Phase 3 ready clinical program in no option refractory disabling angina and recipient of a RMAT designation (USA).

CEO: David J. Mazzo

Telephone: +1 908 842-0100

Address: 110 Allen Road, Basking Ridge 07920, NJ, US

Number of employees: 27

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

62%38%

Bearish Bullish

67%33%

Bearish Bullish

62%38%

TipRanks News for CLBS

Tue, 24 May 2022 13:15 GMT Analysts Offer Insights on Healthcare Companies: Caladrius Biosciences (CLBS) and Alzamend Neuro (ALZN)

- TipRanks. All rights reserved.

Sun, 01 May 2022 12:20 GMT Caladrius Biosciences (CLBS) Receives a Hold from Dawson James

- TipRanks. All rights reserved.

Thu, 28 Apr 2022 08:30 GMT Caladrius Biosciences (CLBS) Gets a Buy Rating from Brookline Capital Markets

- TipRanks. All rights reserved.

Wed, 27 Apr 2022 16:45 GMT Caladrius Biosciences (CLBS) Receives a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

News

Stocktwits